Funding Committees
Cancer Research UK funds across the whole range of cancer research, within Institutes, universities and medical schools throughout the UK.
Cancer Research UK's Research Funding Committee structure is designed to ensure excellence in peer review and provides a balance of strategic and response mode funding streams. Each Committee has its own remit and range of awards and each adheres to a common Code of Practice (PDF, 96KB). Strategic oversight of all Committee activities is taken by the Scientific Executive Board. All funding Committees adhere to the common Terms of Reference (PDF, 76KB).
The Biological Sciences Committee (BSC) is responsible for the oversight, development, review, funding and management of a portfolio of research focused on the basic understanding of cancer.
The Biomarkers and Imaging Discovery and Development Committee (BIDD) reviews, funds and manages research in all types of biomarkers (predisposition, screening, diagnostic, prognostic, predictive, pharmacological and surrogate response) using invasive (i.e., surgical specimens or biofluids) and non-invasive (i.e., imaging) technologies.
More about the Biomarkers and Imaging Discovery and Development Committee.
The Clinical Trials Awards and Advisory Committee (CTAAC) reviews and funds cancer clinical trials. CTAAC is responsible for the review, funding and management of awards for phase I and II studies testing aspects of feasibility or tolerability and/or efficacy, larger phase II and phase III therapeutic clinical trials and sample collections.
More about the Clinical Trials Awards and Advisory Committee.
This Committee is responsible for the oversight, review, funding and management of a comprehensive portfolio of research programmes and projects focused on clinical and translational research, including clinical trials, drug discovery, imaging, surgery and radiotherapy.
More about the Clinical and Translational Research Committee.
The Discovery Committee (DC) was established in September 2003, as a joint funding initiative between Cancer Research UK and Cancer Research Technology (CRT). The aim of this funding scheme is to directly develop research for patient benefit.
The Drug Discovery Advisory Group (DDAG) was established to provide expert scientific advice to the Clinical and Translational Research Committee on the progress, strategy and capabilities of the drug discovery activities within the Cancer Research UK portfolio.
The New Agents Committee (NAC) selects new anti-cancer treatments for early clinical trials. The NAC is interested in proposals for scientifically-driven trials of novel unregistered anti-cancer agents.
The Population Research Committee (PRC) is responsible for the oversight, development, review, funding and management of a portfolio of awards for research Programmes and Projects Grants in population science.
The role of the Scientific Executive Board (SEB) is to develop and implement the organisation’s scientific strategy and policy.
The Cancer Research UK Tobacco Advisory Group (TAG) is a funding and policy-setting committee focussing on several key priority tobacco policy areas. Through the TAG, Cancer Research UK aims to complement its policy and campaigning work by funding related projects and research, as well as other work of national and international significance.
The Training and Career Development Board reviews, funds and manages the portfolio and budget of Cancer Research UK's Fellowship and Bursary Awards. It also plays a guiding role in the training of postdoctoral scientists.
Increase text
Decrease text
Print this page